Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B (Q83258052)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jung-Hwan Yoon

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

6

Hwi Young Kim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Goh Eun Chung

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Won Kim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kook Lae Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jeong-Hoon Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Yong Jin Jung

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Donghee Kim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Ji Bong Jeong

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Byeong Gwan Kim

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Yoon Jun Kim

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Hyo-Suk Lee

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

21 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

number of pages

7

1 reference

Digestive Diseases and Sciences

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

2130-2136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21253834%20AND%20SRC:MED&resulttype=core&format=json

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

20 January 2020

cites work

1 reference

12 December 2020

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

12 December 2020

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

12 December 2020

1 reference

12 December 2020

A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients

1 reference

12 December 2020

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

12 December 2020

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

1 reference

12 December 2020

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.

1 reference

12 December 2020

Cellular and virological mechanisms of HBV drug resistance

1 reference

12 December 2020

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

1 reference

12 December 2020

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

1 reference

12 December 2020

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

1 reference

12 December 2020

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

12 December 2020

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy

1 reference

12 December 2020

The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.

1 reference

12 December 2020

High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance.

1 reference

12 December 2020

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

12 December 2020

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

12 December 2020

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

1 reference

12 December 2020

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

12 December 2020

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

12 December 2020

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

12 December 2020